Amrutanjan Health Care Analyst Review May 2026
- May 21, 2026
- Posted by: Neeraj Pandey
- Category: News
This Amrutanjan Health Care analyst review for May 2026 covers the key data investors need for AMRUTANJAN at its current price of Rs 750. Amrutanjan Health Care (NSE: AMRUTANJAN) is a leading OTC healthcare brand with a market capitalisation of approximately Rs 2,800 crore, known for the Amrutanjan pain balm and healthcare products. The analyst consensus target of Rs 900 implies meaningful upside, and this Amrutanjan Health Care analyst review examines technical levels, business performance, valuation, and key risks for AMRUTANJAN through FY27.
Click Here – Get Free Investment Predictions
Amrutanjan Health Care Company Snapshot May 2026
Amrutanjan’s pain management (Amrutanjan balm), women’s hygiene (Comfy sanitary pads), and healthcare products are growing across Tier 2 and Tier 3 cities. South India dominance and rural distribution expansion drive growth. The table below summarises the key data referenced in this Amrutanjan Health Care analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | AMRUTANJAN |
| Sector | FMCG – OTC Healthcare |
| CMP (May 2026) | Rs 750 |
| 52 Week High | Rs 950 |
| 52 Week Low | Rs 650 |
| Market Cap | Rs 2,800 Crore |
| Trailing P/E | 30x |
| Analyst Consensus Target | Rs 900 |
| Bull Case Target | Rs 1,050 |
| Bear Case Target | Rs 620 |
Analyst Insight in This Amrutanjan Health Care Analyst Review
Senior Research Analyst Ankit Jaiswal flags Amrutanjan Health Care as a stock to watch in May 2026. At Rs 750, Ankit Jaiswal identifies key support in the Rs 663 to Rs 712 band and resistance near Rs 795. He suggests watching Amrutanjan Health Care for a potential move toward Rs 900, subject to FMCG – OTC Healthcare sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Amrutanjan Health Care analyst review and does not constitute a trade recommendation.
Technical Analysis in This Amrutanjan Health Care Analyst Review
At Rs 750, AMRUTANJAN is trading within its 52-week band of Rs 650 to Rs 950. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 663 to Rs 712 band while resistance is seen in the Rs 795 to Rs 825 zone. A sustained move above Rs 795 could open the path toward the analyst consensus target of Rs 900 as identified in this Amrutanjan Health Care analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 663 to Rs 712 – investors tracking this Amrutanjan Health Care analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for AMRUTANJAN.
- Resistance Zone: Rs 795 to Rs 825 – a sustained close above Rs 795 would be a positive breakout signal worth flagging in this Amrutanjan Health Care analyst review.
- Medium-Term Target: The analyst consensus of Rs 900 represents the base-case upside scenario in this Amrutanjan Health Care analyst review.
Business Segment Analysis
Pain Management (Amrutanjan Balm – Core Brand)
This is the primary revenue and margin driver for Amrutanjan Health Care, directly supporting the earnings trajectory toward the consensus target of Rs 900.
Women’s Hygiene (Comfy Sanitary Pads)
This segment adds scale and diversification to Amrutanjan Health Care’s business model and is a meaningful EPS contributor through FY27 and FY28.
Healthcare OTC Products and Supplements
This represents the medium-term growth frontier for Amrutanjan Health Care and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Amrutanjan Health Care Analyst Review
At Rs 750, Amrutanjan Health Care trades at a trailing P/E of 30x. This Amrutanjan Health Care analyst review presents three scenarios: a bull case of Rs 1,050 on strong earnings delivery, a base case of Rs 900 at analyst consensus, and a bear case of Rs 620 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Amrutanjan Health Care analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 1,050 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 900 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 620 | Earnings miss or macro headwinds |
Trade Outlook for Amrutanjan Health Care
Based on the technical and fundamental analysis in this Amrutanjan Health Care analyst review, investors might watch AMRUTANJAN near the support zone of Rs 663 to Rs 712 for potential opportunities. A flag above Rs 795 could suggest improving momentum toward Rs 900. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Amrutanjan Health Care in FY27
A well-rounded Amrutanjan Health Care analyst review must assess downside risks. Key risks for Amrutanjan Health Care include a macro slowdown affecting FMCG – OTC Healthcare sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in AMRUTANJAN.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Amrutanjan Health Care Analyst Review Verdict for 2026
This Amrutanjan Health Care analyst review concludes that at Rs 750, AMRUTANJAN offers a defined risk-reward with a consensus target of Rs 900. The 52-week range of Rs 650 to Rs 950 provides context on the current entry point. Use this Amrutanjan Health Care analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on AMRUTANJAN.
Frequently Asked Questions: Amrutanjan Health Care Analyst Review 2026
What is the analyst target for Amrutanjan Health Care in 2026?
The analyst consensus target is Rs 900, with a bull case of Rs 1,050 and a bear case of Rs 620. This Amrutanjan Health Care analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is Amrutanjan Health Care a good investment at Rs 750?
At Rs 750 with a P/E of 30x and a consensus target of Rs 900, this Amrutanjan Health Care analyst review is constructive for medium to long-term investors in the FMCG – OTC Healthcare sector. Always consult a SEBI-registered advisor before investing.
What is Amrutanjan Health Care’s 52-week high and low?
The 52-week high is Rs 950 and the 52-week low is Rs 650. At Rs 750, AMRUTANJAN is positioned within this range as noted in this Amrutanjan Health Care analyst review.
What are the key risks for Amrutanjan Health Care?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the FMCG – OTC Healthcare sector as assessed in this Amrutanjan Health Care analyst review.
Where can I track live data for Amrutanjan Health Care?
Track Amrutanjan Health Care’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Amrutanjan Health Care analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
